Rongyuan Y. Zhuang

No. 180, Fenglin Rd
Xuhui, 200032, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Management of MOG antibody-associated disease by pembrolizumab and radiation myelopathy in an elderly patient: A case report and literature review.

Management of MOG antibody-associated disease by pembrolizumab and radiation myelopathy in an elderly patient: A case report and literature review.

Journal: Human vaccines & immunotherapeutics

Published: November 25, 2025

A real-world study of active vitamin D as a prognostic marker in patients with sarcoma.

A real-world study of active vitamin D as a prognostic marker in patients with sarcoma.

Journal: Discover oncology

Published: October 08, 2023

Efficacy of nab‑paclitaxel vs. Gemcitabine in combination with S‑1 for advanced pancreatic cancer: A multicenter phase II randomized trial.

Efficacy of nab‑paclitaxel vs. Gemcitabine in combination with S‑1 for advanced pancreatic cancer: A multicenter phase II randomized trial.

Journal: Oncology letters

Published: September 25, 2023

Efficacy and safety of combination therapy with chemotherapy, programmed death-1 inhibitor and anlotinib in the treatment of advanced dedifferentiated liposarcoma

Efficacy and safety of combination therapy with chemotherapy, programmed death-1 inhibitor and anlotinib in the treatment of advanced dedifferentiated liposarcoma

Journal: Zhonghua yi xue za zhi

Published: August 24, 2022

Case report: Pathological complete response to perioperative treatment of radiotherapy combined with angiogenesis inhibitor in a patient with pleomorphic liposarcoma.

Case report: Pathological complete response to perioperative treatment of radiotherapy combined with angiogenesis inhibitor in a patient with pleomorphic liposarcoma.

Journal: Frontiers in oncology

Published: April 21, 2022

Twenty-eight months progression-free survival after pyrotinib therapy for HER2-positive recurrent ovarian clear cell carcinoma: a case report.

Twenty-eight months progression-free survival after pyrotinib therapy for HER2-positive recurrent ovarian clear cell carcinoma: a case report.

Journal: Annals of translational medicine

Published: January 18, 2022

Case Report: Complete Response to Antiangiogenesis and Immune Checkpoint Blockade in an Unresectable MMR-Deficient Leiomyosarcoma Harboring Biallelic Loss of PTEN.

Case Report: Complete Response to Antiangiogenesis and Immune Checkpoint Blockade in an Unresectable MMR-Deficient Leiomyosarcoma Harboring Biallelic Loss of PTEN.

Journal: Frontiers in oncology

Published: October 26, 2021

Activity of PD-1 Inhibitor Combined With Anti-Angiogenic Therapy in Advanced Sarcoma: A Single-Center Retrospective Analysis.

Activity of PD-1 Inhibitor Combined With Anti-Angiogenic Therapy in Advanced Sarcoma: A Single-Center Retrospective Analysis.

Journal: Frontiers in molecular biosciences

Published: July 26, 2021

Efficacy and Resistance of ALK Inhibitors in Two Inflammatory Myofibroblastic Tumor Patients with ALK Fusions Assessed by Whole Exome and RNA Sequencing.

Efficacy and Resistance of ALK Inhibitors in Two Inflammatory Myofibroblastic Tumor Patients with ALK Fusions Assessed by Whole Exome and RNA Sequencing.

Journal: OncoTargets and therapy

Published: July 06, 2020

Integrated genomic and transcriptomic analysis revealed mutation patterns of de-differentiated liposarcoma and leiomyosarcoma.

Integrated genomic and transcriptomic analysis revealed mutation patterns of de-differentiated liposarcoma and leiomyosarcoma.

Journal: BMC cancer

Published: April 02, 2020

Linc00423 as a tumor suppressor in retroperitoneal liposarcoma via activing MAPK signaling pathway through destabilizing of NFATC3.

Linc00423 as a tumor suppressor in retroperitoneal liposarcoma via activing MAPK signaling pathway through destabilizing of NFATC3.

Journal: Cell death & disease

Published: February 07, 2019

Value of plasma SN-38 levels and DPD activity in irinotecan-based individualized chemotherapy for advanced colorectal cancer with heterozygous type UGT1A16 or UGT1A128.

Value of plasma SN-38 levels and DPD activity in irinotecan-based individualized chemotherapy for advanced colorectal cancer with heterozygous type UGT1A16 or UGT1A128.

Journal: Cancer management and research

Published: December 13, 2018

Showing 1-12 of 28

Last Updated: 09/26/2026